DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in EVRYSDI is risdiplam. One supplier is listed for this compound. Additional details are available on the risdiplam profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 213535
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||FOR SOLUTION;ORAL||Strength||0.75MG/ML|
|Approval Date:||Aug 7, 2020||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Aug 7, 2025|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Regulatory Exclusivity Expiration:||Aug 7, 2027|
|Regulatory Exclusivity Use:||TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER|
|Patent:||⤷ Try it Free||Patent Expiration:||Feb 8, 2033||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription